https://www.thestar.com.my/business/business-news/2022/12/06/k-one-made-exclusive-distributor-of-diversey-products-in-malaysia

Q6. At what stage (may be in term of percentage) the development on the ventilator has achieved? How much MIDA Grant has been utilised as at to date?
A6. The development of the ventilator is progressing well. As it is a Class C medical device, i.e. a semi-invasive medical device, it needs to go through numerous clinical trials/tests to ensure that it is safe for use. Therefore, the management would need to work on this with care and have collaborated with 2 prestigious universities in Malaysia to conduct the tests on the ventilator which would be branded as “Medkaire”. Once the clinical trials are completed in the next few months, the application to MDA for its final approval would be submitted. Applications in conjunction with clinical trials are planned for submission for FDA and CE approvals which are necessary for the export markets. The development of the ventilator has taken a long time as it must ensure that the device is safe for use as safety is of utmost importance. The ventilator business is for long term and does not depend on COVID- 19 only as the device can be used for other respiratory diseases or in aiding breathing difficulty.
The Company is thankful for the MIDA Grant. It is progressing well and the management had submitted claims for work done based on milestones achieved.

MOU is an exploration of opportunity. Doesn’t necessarily translate to sales. Cash flow is the blood in the veins and K1 has it for bigger acquisition plans.

Debate is only healthy if it’s based on facts. Investment is long term, don’t be clouded by current negative sentiment. Is the global market, not particularly a single stock.

Name shaming is the lowest in the hierarchy..

A new low for no peculiar reason is understated. No changes in management team, no losses in the past quarter. Revenue increase, ready cash for any potential acquisition. Covid cases going up, but no lockdown. USD at ATH, these are all positive reasons for the share to spike up in the 2H of the year TP rm0.49 Mid Term, rm0.75 Long Term

With the RM weakening 6% again the greenback considering K1 major client is overseas, it should be a good sign to accumulate

Volume should improve in 2 weeks time. Consolidating mode. New investor funds needed. K1 not aggressive enough in marketing effort..

Debt Level: K1 is debt free.

Reducing Debt: K1 had no debt 5 years ago.

https://vaxine.net/tga-grants-provisional-determination-to-vaxine-for-its-covid-19-recombinant-protein-vaccine/

How Easily Can K-One Technology Berhad Raise Cash?

While K-One Technology Berhad seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

K-One Technology Berhad's cash burn of RM11m is about 11% of its RM96m market capitalisation. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

Current : https://www.tga.gov.au/covid-19-vaccine-provisional-determinations

15 December 2021 Vaxine Pty Ltd Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed) Recombinant protein

Previous : https://www.klsescreener.com/v2/announcements/view/3269743

MEMORANDUM OF UNDERSTANDING Memorandum of Understanding ("MOU") on manufacture and/or distribution of COVID-19 vaccine ("Covax-19") between K-One MediTech Sdn Bhd ("K-One MediTech") and Vaxine Pty Ltd, Australia ("Vaxine")

Supply & Demand

Collaboration Agreement w Selia Tek

https://www.klsescreener.com/v2/announcements/view/3260035

WHO - shortage of Syringe 2022

https://www.theedgemarkets.com/article/sufficient-covid-vaccine-syringes-malaysia-good-opportunity-exporters-say-suppliers

steady price since last week, FED rate hikes USD $ high, all showing good sign for company that has 80% business ovs. p0.355p

https://www.google.com.my/amp/s/www.einnews.com/amp/pr_news/541113168/covid-19-vaccine-breakthrough

https://www.theedgemarkets.com/article/medical-device-authority-gives-green-light-kone-unit-sell-low-deadvolume-disposable-syringes

https://www.google.com.my/amp/s/www.astroawani.com/berita-malaysia/why-low-deadvolume-syringes-are-used-covid-vaccine-injections-283887%3famp=1